D
ORIC Pharmaceuticals, Inc.
ORIC
$5.78
$0.254.52%
D
Sell
6/21/2023Upgraded
ORIC Pharmaceuticals, Inc. (ORIC) was upgraded to D- from E+ on 6/21/2023 due to an increase in the total return index and volatility index.
ORIC Pharmaceuticals, Inc. (ORIC) was upgraded to D- from E+ on 6/21/2023 due to an increase in the total return index and volatility index.
E
Sell
6/5/2023Downgrade
ORIC Pharmaceuticals, Inc. (ORIC) was downgraded to E+ from D- on 6/5/2023 due to a decline in the volatility index.
ORIC Pharmaceuticals, Inc. (ORIC) was downgraded to E+ from D- on 6/5/2023 due to a decline in the volatility index.
D
Sell
5/15/2023Upgraded
ORIC Pharmaceuticals, Inc. (ORIC) was upgraded to D- from E+ on 5/15/2023 due to an increase in the volatility index.
ORIC Pharmaceuticals, Inc. (ORIC) was upgraded to D- from E+ on 5/15/2023 due to an increase in the volatility index.
E
Sell
5/10/2023Downgrade
ORIC Pharmaceuticals, Inc. (ORIC) was downgraded to E+ from D- on 5/10/2023 due to a decline in the total return index, volatility index and growth index.
ORIC Pharmaceuticals, Inc. (ORIC) was downgraded to E+ from D- on 5/10/2023 due to a decline in the total return index, volatility index and growth index.
D
Sell
4/24/2023Upgraded
ORIC Pharmaceuticals, Inc. (ORIC) was upgraded to D- from E+ on 4/24/2023 due to an increase in the volatility index.
ORIC Pharmaceuticals, Inc. (ORIC) was upgraded to D- from E+ on 4/24/2023 due to an increase in the volatility index.
E
Sell
4/6/2023Downgrade
ORIC Pharmaceuticals, Inc. (ORIC) was downgraded to E+ from D- on 4/6/2023 due to a decline in the volatility index.
ORIC Pharmaceuticals, Inc. (ORIC) was downgraded to E+ from D- on 4/6/2023 due to a decline in the volatility index.
D
Sell
3/20/2023Upgraded
ORIC Pharmaceuticals, Inc. (ORIC) was upgraded to D- from E+ on 3/20/2023 due to an increase in the growth index, volatility index and solvency index. Operating cash flow increased 20.66% from -$19.32M to -$15.33M, and earnings per share increased from -$0.63 to -$0.5195.
ORIC Pharmaceuticals, Inc. (ORIC) was upgraded to D- from E+ on 3/20/2023 due to an increase in the growth index, volatility index and solvency index. Operating cash flow increased 20.66% from -$19.32M to -$15.33M, and earnings per share increased from -$0.63 to -$0.5195.
E
Sell
3/14/2023Downgrade
ORIC Pharmaceuticals, Inc. (ORIC) was downgraded to E+ from D- on 3/14/2023 due to a decline in the total return index.
ORIC Pharmaceuticals, Inc. (ORIC) was downgraded to E+ from D- on 3/14/2023 due to a decline in the total return index.
D
Sell
2/23/2023Upgraded
ORIC Pharmaceuticals, Inc. (ORIC) was upgraded to D- from E+ on 2/23/2023 due to an increase in the total return index and valuation index.
ORIC Pharmaceuticals, Inc. (ORIC) was upgraded to D- from E+ on 2/23/2023 due to an increase in the total return index and valuation index.
E
Sell
2/8/2023Downgrade
ORIC Pharmaceuticals, Inc. (ORIC) was downgraded to E+ from D- on 2/8/2023 due to a decline in the volatility index and valuation index.
ORIC Pharmaceuticals, Inc. (ORIC) was downgraded to E+ from D- on 2/8/2023 due to a decline in the volatility index and valuation index.
D
Sell
11/14/2022Downgrade
ORIC Pharmaceuticals, Inc. (ORIC) was downgraded to D- from D on 11/14/2022 due to a noticeable decline in the growth index and solvency index. Earnings per share declined from -$0.5138 to -$0.63, the quick ratio declined from 18.2 to 14.58, and operating cash flow declined 8.69% from -$17.78M to -$19.32M.
ORIC Pharmaceuticals, Inc. (ORIC) was downgraded to D- from D on 11/14/2022 due to a noticeable decline in the growth index and solvency index. Earnings per share declined from -$0.5138 to -$0.63, the quick ratio declined from 18.2 to 14.58, and operating cash flow declined 8.69% from -$17.78M to -$19.32M.
D
Sell
11/11/2022Upgraded
ORIC Pharmaceuticals, Inc. (ORIC) was upgraded to D from D- on 11/11/2022 due to an increase in the volatility index and valuation index.
ORIC Pharmaceuticals, Inc. (ORIC) was upgraded to D from D- on 11/11/2022 due to an increase in the volatility index and valuation index.
D
Sell
10/11/2022Downgrade
ORIC Pharmaceuticals, Inc. (ORIC) was downgraded to D- from D on 10/11/2022 due to a decline in the volatility index and total return index.
ORIC Pharmaceuticals, Inc. (ORIC) was downgraded to D- from D on 10/11/2022 due to a decline in the volatility index and total return index.
D
Sell
9/23/2022Upgraded
ORIC Pharmaceuticals, Inc. (ORIC) was upgraded to D from D- on 9/23/2022 due to an increase in the volatility index.
ORIC Pharmaceuticals, Inc. (ORIC) was upgraded to D from D- on 9/23/2022 due to an increase in the volatility index.
D
Sell
9/6/2022Downgrade
ORIC Pharmaceuticals, Inc. (ORIC) was downgraded to D- from D on 9/6/2022 due to a decline in the volatility index.
ORIC Pharmaceuticals, Inc. (ORIC) was downgraded to D- from D on 9/6/2022 due to a decline in the volatility index.
D
Sell
8/19/2022Upgraded
ORIC Pharmaceuticals, Inc. (ORIC) was upgraded to D from D- on 8/19/2022 due to an increase in the growth index, volatility index and total return index. Operating cash flow increased 21.75% from -$22.72M to -$17.78M, earnings per share increased from -$0.5873 to -$0.5138, and EBIT increased 11.02% from -$23.26M to -$20.7M.
ORIC Pharmaceuticals, Inc. (ORIC) was upgraded to D from D- on 8/19/2022 due to an increase in the growth index, volatility index and total return index. Operating cash flow increased 21.75% from -$22.72M to -$17.78M, earnings per share increased from -$0.5873 to -$0.5138, and EBIT increased 11.02% from -$23.26M to -$20.7M.
D
Sell
5/31/2022Upgraded
ORIC Pharmaceuticals, Inc. (ORIC) was upgraded to D- from E+ on 5/31/2022 due to an increase in the volatility index.
ORIC Pharmaceuticals, Inc. (ORIC) was upgraded to D- from E+ on 5/31/2022 due to an increase in the volatility index.
E
Sell
5/13/2022Downgrade
ORIC Pharmaceuticals, Inc. (ORIC) was downgraded to E+ from D- on 5/13/2022 due to a decline in the volatility index, solvency index and total return index.
ORIC Pharmaceuticals, Inc. (ORIC) was downgraded to E+ from D- on 5/13/2022 due to a decline in the volatility index, solvency index and total return index.
D
Sell
5/5/2022Upgraded
ORIC Pharmaceuticals, Inc. (ORIC) was upgraded to D- from E+ on 5/5/2022 due to an increase in the valuation index.
ORIC Pharmaceuticals, Inc. (ORIC) was upgraded to D- from E+ on 5/5/2022 due to an increase in the valuation index.
E
Sell
4/20/2022Downgrade
ORIC Pharmaceuticals, Inc. (ORIC) was downgraded to E+ from D- on 4/20/2022 due to a decline in the growth index and total return index. Operating cash flow declined 34.11% from -$12.14M to -$16.28M, EBIT declined 23.56% from -$18.46M to -$22.81M, and earnings per share declined from -$0.4724 to -$0.5781.
ORIC Pharmaceuticals, Inc. (ORIC) was downgraded to E+ from D- on 4/20/2022 due to a decline in the growth index and total return index. Operating cash flow declined 34.11% from -$12.14M to -$16.28M, EBIT declined 23.56% from -$18.46M to -$22.81M, and earnings per share declined from -$0.4724 to -$0.5781.
D
Sell
3/22/2022Downgrade
ORIC Pharmaceuticals, Inc. (ORIC) was downgraded to D- from D on 3/22/2022 due to a decline in the volatility index and total return index.
ORIC Pharmaceuticals, Inc. (ORIC) was downgraded to D- from D on 3/22/2022 due to a decline in the volatility index and total return index.
D
Sell
2/25/2022Upgraded
ORIC Pharmaceuticals, Inc. (ORIC) was upgraded to D from D- on 2/25/2022 due to an increase in the volatility index and valuation index.
ORIC Pharmaceuticals, Inc. (ORIC) was upgraded to D from D- on 2/25/2022 due to an increase in the volatility index and valuation index.
D
Sell
2/9/2022Downgrade
ORIC Pharmaceuticals, Inc. (ORIC) was downgraded to D- from D on 2/9/2022 due to a decline in the volatility index and total return index.
ORIC Pharmaceuticals, Inc. (ORIC) was downgraded to D- from D on 2/9/2022 due to a decline in the volatility index and total return index.
D
Sell
11/9/2021Upgraded
ORIC Pharmaceuticals, Inc. (ORIC) was upgraded to D from D- on 11/9/2021 due to an increase in the growth index, volatility index and total return index. Operating cash flow increased 25.11% from -$16.21M to -$12.14M, earnings per share increased from -$0.5724 to -$0.4724, and EBIT increased 12.35% from -$21.06M to -$18.46M.
ORIC Pharmaceuticals, Inc. (ORIC) was upgraded to D from D- on 11/9/2021 due to an increase in the growth index, volatility index and total return index. Operating cash flow increased 25.11% from -$16.21M to -$12.14M, earnings per share increased from -$0.5724 to -$0.4724, and EBIT increased 12.35% from -$21.06M to -$18.46M.
D
Sell
11/3/2021Downgrade
ORIC Pharmaceuticals, Inc. (ORIC) was downgraded to D- from D on 11/3/2021 due to a decline in the volatility index and total return index.
ORIC Pharmaceuticals, Inc. (ORIC) was downgraded to D- from D on 11/3/2021 due to a decline in the volatility index and total return index.
D
Sell
10/4/2021Upgraded
ORIC Pharmaceuticals, Inc. (ORIC) was upgraded to D from D- on 10/4/2021 due to an increase in the valuation index and total return index.
ORIC Pharmaceuticals, Inc. (ORIC) was upgraded to D from D- on 10/4/2021 due to an increase in the valuation index and total return index.
D
Sell
9/17/2021Downgrade
ORIC Pharmaceuticals, Inc. (ORIC) was downgraded to D- from D on 9/17/2021 due to a major decline in the efficiency index, total return index and volatility index. Net income declined 27.26% from -$16.51M to -$21.01M, and total capital declined 6.54% from $278.14M to $259.94M.
ORIC Pharmaceuticals, Inc. (ORIC) was downgraded to D- from D on 9/17/2021 due to a major decline in the efficiency index, total return index and volatility index. Net income declined 27.26% from -$16.51M to -$21.01M, and total capital declined 6.54% from $278.14M to $259.94M.
D
Sell
11/16/2020Upgraded
ORIC Pharmaceuticals, Inc. (ORIC) was upgraded to D from E on 11/16/2020 due to an increase in the volatility index.
ORIC Pharmaceuticals, Inc. (ORIC) was upgraded to D from E on 11/16/2020 due to an increase in the volatility index.
E
Sell
10/1/2020Upgraded
ORIC Pharmaceuticals, Inc. (ORIC) was upgraded to E from E- on 10/1/2020 due to an increase in the valuation index.
ORIC Pharmaceuticals, Inc. (ORIC) was upgraded to E from E- on 10/1/2020 due to an increase in the valuation index.
E
Sell
8/10/2020Downgrade
ORIC Pharmaceuticals, Inc. (ORIC) was downgraded to E- from E on 8/10/2020 due to a decline in the volatility index and valuation index.
ORIC Pharmaceuticals, Inc. (ORIC) was downgraded to E- from E on 8/10/2020 due to a decline in the volatility index and valuation index.
E
Sell
8/7/2020None
ORIC Pharmaceuticals, Inc. (ORIC) was downgraded to E from U on 08/07/2020.
ORIC Pharmaceuticals, Inc. (ORIC) was downgraded to E from U on 08/07/2020.
NASDAQ
04/02/2025 4:00PM Eastern
Quotes delayed
